[1] |
BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
|
[2] |
MAZZAFERRO V, REGALIA E, DOCI R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J]. N Engl J Med, 1996, 334(11): 693-699. DOI: 10.1056/NEJM199603143341104.
|
[3] |
XU X, LU D, LING Q, et al. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria[J]. Gut, 2016, 65(6): 1035-1041. DOI: 10.1136/gutjnl-2014-308513.
|
[4] |
SAPISOCHIN G, BRUIX J. Liver transplantation for hepatocellular carcinoma: Outcomes and novel surgical approaches[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(4): 203-217. DOI: 10.1038/nrgastro.2016.193.
|
[5] |
ZAVAGLIA C, de CARLIS L, ALBERTI AB, et al. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma[J]. Am J Gastroenterol, 2005, 100(12): 2708-2716. DOI: 10.1111/j.1572-0241.2005.00289.x.
|
[6] |
REN A, LI Z, ZHOU X, et al. Evaluation of the alpha-fetoprotein model for predicting recurrence and survival in patients with hepatitis B virus (HBV)-related cirrhosis who received liver transplantation for hepatocellular carcinoma[J]. Front Surg, 2020, 7: 52. DOI: 10.3389/fsurg.2020.00052.
|
[7] |
ZHANG X, WU Z, PENG Y, et al. Correlationship between Ki67, VEGF, and p53 and hepatocellular carcinoma recurrence in liver transplant patients[J]. Biomed Res Int, 2021, 2021: 6651397. DOI: 10.1155/2021/6651397.
|
[8] |
FENG J, ZHU R, FENG D, et al. Prediction of early recurrence of solitary hepatocellular carcinoma after orthotopic liver transplantation[J]. Sci Rep, 2019, 9(1): 15855. DOI: 10.1038/s41598-019-52427-8.
|
[9] |
COUSSENS LM, WERB Z. Inflammation and cancer[J]. Nature, 2002, 420(6917): 860-867. DOI: 10.1038/nature01322.
|
[10] |
COFFELT SB, de VISSER KE. Cancer: Inflammation lights the way to metastasis[J]. Nature, 2014, 507(7490): 48-49. DOI: 10.1038/nature13062.
|
[11] |
AINO H, SUMIE S, NⅡZEKI T, et al. The systemic inflammatory response as a prognostic factor for advanced hepatocellular carcinoma with extrahepatic metastasis[J]. Mol Clin Oncol, 2016, 5(1): 83-88. DOI: 10.3892/mco.2016.879.
|
[12] |
MOTOMURA T, SHIRABE K, MANO Y, et al. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment[J]. J Hepatol, 2013, 58(1): 58-64. DOI: 10.1016/j.jhep.2012.08.017.
|
[13] |
XU ZG, YE CJ, LIU LX, et al. The pretransplant neutrophil-lymphocyte ratio as a new prognostic predictor after liver transplantation for hepatocellular cancer: A systematic review and meta-analysis[J]. Biomark Med, 2018, 12(2): 189-199. DOI: 10.2217/bmm-2017-0307.
|
[14] |
SULLIVAN LM, MASSARO JM, SR DRB. Presentation of multivariate data for clinical use: The Framingham Study risk score functions[J]. Stat Med, 2004, 23(10): 1631-1660. DOI: 10.1002/sim.1742.
|
[15] |
JOU Y, HUANG C, CHO H. A VIF-based optimization model to alleviate collinearity problems in multiple linear regression[J]. Computational Statistics, 2014, 29(6): 1515-1541. DOI: 10.1007/s00180-014-0504-3.
|
[16] |
MA E, LI J, XING H, et al. Development of a predictive nomogram for early recurrence of hepatocellular carcinoma in patients undergoing liver transplantation[J]. Ann Transl Med, 2021, 9(6): 468. DOI: 10.21037/atm-21-334.
|
[17] |
MA KW, SHE WH, CHAN A, et al. Validated model for prediction of recurrent hepatocellular carcinoma after liver transplantation in Asian population[J]. World J Gastrointest Oncol, 2019, 11(4): 322-334. DOI: 10.4251/wjgo.v11.i4.322.
|
[18] |
SHIMAMURA T, AKAMATSU N, FUJIYOSHI M, et al. Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: The 5-5-500 rule-a retrospective study[J]. Transpl Int, 2019, 32(4): 356-368. DOI: 10.1111/tri.13391.
|
[19] |
SHI K, LI P, XUE D, et al. Neutrophil-lymphocyte ratio and the risk of hepatocellular carcinoma in patients with hepatitis B-caused cirrhosis[J]. Eur J Gastroenterol Hepatol, 2021, 33(1S Suppl 1): e686-e692. DOI: 10.1097/MEG.0000000000002217.
|
[20] |
SILVA TH, SCHILITHZ A, PERES W, et al. Neutrophil-lymphocyte ratio and nutritional status are clinically useful in predicting prognosis in colorectal cancer patients[J]. Nutr Cancer, 2020, 72(8): 1345-1354. DOI: 10.1080/01635581.2019.1679198.
|
[21] |
CHEN L, QI L, ZHANG J, et al. Neutrophil-lymphocyte ratio as a prognostic factor for minute clear cell renal cell carcinoma diagnosed using multi-slice spiral CT[J]. Medicine (Baltimore), 2021, 100(23): e26292. DOI: 10.1097/MD.0000000000026292.
|
[22] |
KOTEISH A, THULUVATH PJ. Screening for hepatocellular carcinoma[J]. J Vasc Interv Radiol, 2002, 13(9 Pt 2): s185-s190. DOI: 10.1016/s1051-0443(07)61785-0.
|
[23] |
JIANG N, ZENG KN, DOU KF, et al. Preoperative alfa-fetoprotein and fibrinogen predict hepatocellular carcinoma recurrence after liver transplantation regardless of the Milan criteria: model development with external validation[J]. Cell Physiol Biochem, 2018, 48(1): 317-327. DOI: 10.1159/000491731.
|
[24] |
HALAZUN KJ, NAJJAR M, ABDELMESSIH RM, et al. Recurrence after liver transplantation for hepatocellular carcinoma: A new MORAL to the story[J]. Ann Surg, 2017, 265(3): 557-564. DOI: 10.1097/SLA.0000000000001966.
|
[25] |
FENG J, WU J, ZHU R, et al. Simple risk score for prediction of early recurrence of hepatocellular carcinoma within the Milan criteria after orthotopic liver transplantation[J]. Sci Rep, 2017, 7: 44036. DOI: 10.1038/srep44036.
|
[26] |
MEHTA N, HEIMBACH J, HARNOIS DM, et al. Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant[J]. JAMA Oncol, 2017, 3(4): 493-500. DOI: 10.1001/jamaoncol.2016.5116.
|
[27] |
JIANG P, JIA M, HU J, et al. Prognostic value of Ki67 in patients with stage 1-2 endometrial cancer: Validation of the cut-off value of Ki67 as a predictive factor[J]. Onco Targets Ther, 2020, 13: 10841-10850. DOI: 10.2147/OTT.S274420.
|
[28] |
CSERNI G, VÖRÖS A, LIEPNIECE-KARELE I, et al. Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off values[J]. Breast, 2014, 23(3): 259-263. DOI: 10.1016/j.breast.2014.02.003.
|
[29] |
WILKINS AC, GUSTERSON B, SZIJGYARTO Z, et al. Ki67 Is an independent predictor of recurrence in the largest randomized trial of 3 radiation fractionation schedules in localized prostate cancer[J]. Int J Radiat Oncol Biol Phys, 2018, 101(2): 309-315. DOI: 10.1016/j.ijrobp.2018.01.072.
|
[30] |
GRANT L, BANERJI S, MURPHY L, et al. Androgen receptor and Ki67 expression and survival outcomes in non-small cell lung cancer[J]. Horm Cancer, 2018, 9(4): 288-294. DOI: 10.1007/s12672-018-0336-7.
|
[31] |
JACOBSEN F, KOHSAR J, GEBAUER F, et al. Loss of p16 and high Ki67 labeling index is associated with poor outcome in esophageal carcinoma[J]. Oncotarget, 2020, 11(12): 1007-1016. DOI: 10.18632/oncotarget.27507.
|
[32] |
TEMRAZ S, SHAMSEDDINE A, MUKHERJI D, et al. Ki67 and P53 in relation to disease progression in metastatic pancreatic cancer: A single institution analysis[J]. Pathol Oncol Res, 2019, 25(3): 1059-1066. DOI: 10.1007/s12253-018-0464-y.
|
[1] | Wenjing NI, Nan GENG, Xue BAI, Jie LI. An excerpt of EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease in 2024[J]. Journal of Clinical Hepatology, 2024, 40(8): 1567-1574. doi: 10.12449/JCH240810 |
[2] | Xiaoyong DUO, Shijie ZHANG, Hongwei ZHANG, Jing YANG, Wenqiang WANG, Linzhi YU, Baocai ZHANG, Yicheng ZHUO, Yunchao JIA, Yan PENG, Shuai HU. Association between gallstones and metabolic syndrome in southern Xinjiang, China[J]. Journal of Clinical Hepatology, 2022, 38(8): 1859-1864. doi: 10.3969/j.issn.1001-5256.2022.08.026 |
[3] | CHEN Huan, LI Ting, WANG ZiJie, WANG ZhongQiong, LUO Gang, DENG MingMing. Influence of metabolic syndrome and its components on the prognosis of patients with pancreatic cancer[J]. Journal of Clinical Hepatology, 2020, 36(12): 2788-2794. doi: 10.3969/j.issn.1001-5256.2020.12.029 |
[4] | Tian Tian, Hu WenWei, Li Xue, Li Ji, Zhang Dan, Li ZhangZheng. Metabolic characteristics of nonalcoholic fatty liver disease and related risk factors in non-obese population[J]. Journal of Clinical Hepatology, 2020, 36(6): 1310-1313. doi: 10.3969/j.issn.1001-5256.2020.06.024 |
[5] | Niu ChunYan, Liu Qin, Luo XiaoChun. Reexamination of the diagnosis of fatty liver disease under the background of disease spectrum progression[J]. Journal of Clinical Hepatology, 2020, 36(10): 2356-2359. doi: 10.3969/j.issn.1001-5256.2020.10.043 |
[6] | Chinese Society of EndocrinologyChinese Medical Association. Consensus for diagnosis and treatment of nonalcoholic fatty liver diseases and metabolic disorders (2nd Edition)[J]. Journal of Clinical Hepatology, 2018, 34(10): 2103-2108. doi: 10.3969/j.issn.1001-5256.2018.10.010 |
[7] | Wu QiQi, Ma Yan, Wang XiaoBo, Xu Qiang, Wang Yan, Bai Li. Influence of metabolic syndrome on significant hepatic fibrosis in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2018, 34(12): 2572-2577. doi: 10.3969/j.issn.1001-5256.2018.12.013 |
[8] | Zhou BingBing, Wang XueMei, Zhang Qian, Xu ShiYi, Dan ZhongYan, Lai YaXin, Wang HaoYu. Association between metabolic syndrome and gallstones[J]. Journal of Clinical Hepatology, 2017, 33(5): 880-882. doi: 10.3969/j.issn.1001-5256.2017.05.017 |
[9] | Xu BeiBei, Wang BingYuan. Nonalcoholic fatty liver disease and serum uric acid[J]. Journal of Clinical Hepatology, 2016, 32(3): 437-441. doi: 10.3969/j.issn.1001-5256.2016.03.007 |
[10] | Li LiangPing. Nonalcoholic fatty liver disease and hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(3): 432-436. doi: 10.3969/j.issn.1001-5256.2016.03.006 |
[11] | Fan JianGao, Yan ShiYan. Metabolic syndrome and fatty liver[J]. Journal of Clinical Hepatology, 2016, 32(3): 407-410. doi: 10.3969/j.issn.1001-5256.2016.03.001 |
[12] | Zhao HongXin, Yan Rong, Niu ChunYan, Zhou YongLi, Wang Jia, Cao RuiQi. Prevalence and associated risk factors for obesity and nonalcoholic fatty liver disease in adolescents in Xi′an, Shaanxi province, China[J]. Journal of Clinical Hepatology, 2015, 31(8): 1248-1251. doi: 10.3969/j.issn.1001-5256.2015.08.016 |
[13] | Huang Ying, Chen Hong. Research progress in association between nonalcoholic fatty liver disease and gallstone disease[J]. Journal of Clinical Hepatology, 2014, 30(11): 1217-1220. doi: 10.3969/j.issn.1001-5256.2014.11.033 |
[14] | Fan JianGao, Zhu ChanYan. Strengthening research on relationship between metabolic syndrome and chronic liver disease[J]. Journal of Clinical Hepatology, 2013, 29(12): 881-884. doi: 10.3969/j.issn.1001-5256.2013.12.001 |
[15] | Yan Jie, Xie Wen. Relationship between metabolic syndrome and chronic hepatitis C[J]. Journal of Clinical Hepatology, 2013, 29(12): 887-889. doi: 10.3969/j.issn.1001-5256.2013.12.003 |
[16] | Li LiangPing, Zhong Huang. The study of cytokeratin 18 fragments and inflammation related factors in non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2012, 28(5): 359-363. |
[17] | Zhang YiNing, Du HongWei, Liu YanJun, Wang ChaoXia. The diagnosis and risk factors for evaluation of nonalcoholic fatty liver disease in children and adolescents[J]. Journal of Clinical Hepatology, 2011, 27(7): 690-693. |
[18] | Wu Tao, Yin ShouYi, Wang HongZhang, Zhang Hong, Jia Wei, Ji Guang. The clinical features and risk factors of patient with metabolic syndrome combined with non-alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2011, 27(10): 1036-1040. |
[19] | Ruan JianWen, Yang Jing, Gao LiJuan. Advances in the relationship between metabolic syndrome and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2011, 27(10): 1102-1105. |
[20] | Niu ChunYan, Yan Rong, Tian Yu, Ma HuiXia, Jiao ShuJiang. The prevalence of fatty liver disease and its relationship with metabolic syndrome[J]. Journal of Clinical Hepatology, 2010, 26(2): 167-169. |